Aside from autoimmunity, an analysis of the tie between psoriasis and thyroid diseases is provided.
In the final analysis of the OPAL Balance study, researchers assessed the safety, tolerability, and efficacy of tofacitinib in patients with active psoriatic arthritis.
Researchers described driving difficulties among patients with axial spondyloarthritis and characterized clinical and sociodemographic features and impact on work.
For patients with psoriatic arthritis, upadacitinib at a dose of 15 mg or 30 mg once daily is more effective than placebo.
A plenary session at the 2020 GRAPPA Annual Meeting was focused on the perspectives of the management of psoriasis and psoriatic arthritis during the COVID-19 pandemic.
Researchers evaluated gastrointestinal-related adverse events in patients with psoriatic arthritis and ankylosing spondylitis who were initiating secukinumab.
Investigators assessed the effect of withdrawing ixekizumab in patients with psoriatic arthritis with minimal disease activity after open-label ixekizumab treatment.
Researchers sought to determine if a higher cumulative pain intensity is associated with premature mortality risk in patients with PsA.
Researchers assessed the overall real-life 6- and 12-month retention rates of secukinumab in patients with psoriatic arthritis in Europe. They also assessed remission, low-disease activity, and response rates of secukinumab.
The DISCOVER-2 study aimed to evaluate multiple clinical outcomes including joint and skin symptoms and radiographic progression in patients with psoriatic arthritis.